Obesity Drug Guidelines: What GRADE Says Actually Works

The newest obesity-drug guidance makes the ranking clearer than the access problem. A 2026 joint statement from three major U.S. obesity organizations gave its strongest recommendations to tirzepatide and semaglutide 2.4 mg, while older medications received conditional or lower-certainty support. Yet only about 1.6% of eligible U.S. adults receive any obesity pharmacotherapy. The drugs with the best evidence often remain the hardest to obtain.

This matters because GRADE—the framework used by the guidelines—does more than tally pounds lost. It evaluates certainty in the evidence and weighs benefits, harms, and practical considerations. It cannot make a monthly bill disappear, and it cannot turn indirect comparisons into head-to-head trials.

What the guidelines actually recommend

The American Gastroenterological Association guideline, published in 2022, made one strong recommendation: add pharmacotherapy to lifestyle intervention for appropriate adults with obesity or overweight. It made only conditional suggestions for individual drugs. Semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER received moderate-certainty suggestions. Phentermine and diethylpropion received low-certainty suggestions. The panel suggested against orlistat.

The 2026 TOS/OMA/OAC guidance statement updated the GRADE assessment across FDA-approved adult obesity drugs and included tirzepatide, which was not yet available for obesity when the AGA published its guideline. It gave its strongest recommendations to tirzepatide and semaglutide, while older agents generally received conditional or downgraded designations.

The guidelines do not fully agree on orlistat. The AGA suggests against it; the newer joint statement conditionally supports it. That disagreement is instructive. GRADE is structured, but panels still decide how much modest weight loss, adverse effects, cost, and generic availability should count. A framework can discipline judgment. It cannot eliminate it.

The efficacy hierarchy starts with tirzepatide and semaglutide

Semaglutide 2.4 mg earned its place through large randomized trials. In STEP 1, 1,961 adults without diabetes received once-weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks. Mean body-weight reduction was about 15.3% with semaglutide and 2.6% with placebo. At least 5% weight loss occurred in 86.4% of semaglutide participants, compared with 31.5% of placebo participants. A 2025 Cochrane review found the pooled STEP evidence pointed in the same direction.

Tirzepatide produced larger average losses in its own trial program. The extended SURMOUNT-1 analysis followed adults without diabetes for 72 weeks. Mean weight reduction was about 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, versus about 3.1% with placebo. A separate Cochrane review of tirzepatide confirmed the overall trial direction.

At maximum doses, comparing those trials suggests tirzepatide exceeds semaglutide by roughly 5 to 7 percentage points of body weight. That is useful context, not a settled direct comparison. No randomized trial in this evidence base directly compared FDA-approved obesity medications against one another. STEP 1 and SURMOUNT-1 had different designs and potentially different populations, so their results cannot prove that one drug beats the other by a fixed amount in the same patient.

A 2025 network meta-analysis provides the most systematic cross-drug comparison available. It ranked tirzepatide above semaglutide, followed by phentermine-topiramate; naltrexone-bupropion and liraglutide occupied a lower, broadly similar tier; phentermine and diethylpropion ranked below them; and orlistat ranked last. Network meta-analysis is stronger than casual cross-trial arithmetic, but it still depends on indirect links among studies. It does not replace a properly randomized head-to-head trial.

Weight loss is not the only outcome

Semaglutide has evidence that older obesity drugs largely lack: a large cardiovascular outcomes trial. In the SELECT trial, 17,604 adults with established cardiovascular disease, overweight or obesity, and no diabetes had sustained weight reduction of about 10.2% at four years with semaglutide. The trial also reported a 20% reduction in major adverse cardiovascular events in this high-risk population. That result supports cardiovascular benefit for this specific population; it does not establish the same benefit for every person taking semaglutide or for tirzepatide.

Tirzepatide has also shown cardiometabolic effects beyond the scale. A SURMOUNT-1 blood-pressure analysis found clinically meaningful reductions in systolic and diastolic blood pressure across weight-loss strata. In people with obesity and mildly reduced or preserved-ejection-fraction heart failure, a 2025 meta-analysis of six randomized trials involving 7,282 participants found incretin-based therapies reduced cardiovascular death or worsening heart failure, with a hazard ratio of 0.74 and a 95% confidence interval of 0.63 to 0.88. That pooled finding applies to the obesity-HFpEF phenotype, not to obesity treatment broadly.

The trade-offs GRADE cannot make vanish

Large weight loss includes more than fat loss. The SURMOUNT-1 body-composition substudy found that tirzepatide-related weight loss included reductions in fat mass and lean mass. A network meta-analysis of GLP-1-based drugs found lean-mass loss across the class. The long-term functional consequences remain uncertain, especially for older adults and people with sarcopenia. Resistance training and adequate protein are sensible clinical countermeasures, but neither converts this concern into a solved problem.

Gastrointestinal adverse effects are common enough to affect persistence. Across key STEP and SURMOUNT trials, nausea occurred in roughly 44% to 59% of participants and vomiting in roughly 24% to 29%. Trial results describe outcomes among people who enrolled, titrated treatment, and remained under close follow-up. In ordinary care, adherence, side effects, and payment barriers narrow the gap between efficacy on paper and benefit in a community.

Stopping treatment is another constraint. STEP and SURMOUNT extension evidence documents near-complete weight regain within one to two years after discontinuation. These medicines treat a chronic condition while patients take them; they have not shown that they permanently reset body-weight regulation. Any decision to start one should include a plan for duration, monitoring, strength and nutrition, adverse effects, and what happens if coverage ends.

The practical verdict

For adults with a clinical indication and reliable access, current GRADE-based guidance supports tirzepatide or semaglutide 2.4 mg over older approved options. Tirzepatide has the highest estimated weight-loss efficacy, but its apparent advantage over semaglutide remains indirect. Semaglutide has the clearest long-term cardiovascular-outcomes evidence in adults with established cardiovascular disease and no diabetes.

When newer agents are unavailable, phentermine-topiramate has the strongest comparative evidence among the older medications. Orlistat has the weakest place in the hierarchy and remains the only drug that one major guideline explicitly recommends against. The harder conclusion is structural: evidence has sorted the options more clearly than the health system has made them available. A guideline can rank treatments. It cannot prescribe insurance coverage.